Preclinical evaluation of a 64Cu-labeled αvβ6-targeting peptide PET probe for pancreatic cancer: from radiometal production to molecular probe validation | Synapse
March 3, 2026
Preclinical evaluation of a 64Cu-labeled αvβ6-targeting peptide PET probe for pancreatic cancer: from radiometal production to molecular probe validation
Puntos clave
The 64Cu-labeled αvβ6-targeting peptide PET probe effectively targets pancreatic cancer.
In vitro and in vivo studies demonstrate high specificity with a significant uptake in pancreatic tumor tissues.
This study utilizes advanced radiometal production techniques for the probe synthesis and validation.
These findings suggest a promising new tool for early diagnosis of pancreatic cancer, though clinical trials are needed.